Trial · NCT00759772
The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
NCT00759772, Phase 2, Completed, Massachusetts General Hospital; results first posted 2017-03-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa. Trials, record NCT00759772. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00759772
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
- NCT number
- NCT00759772
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Anorexia Nervosa, Osteoporosis
- Interventions
- Placebo, Teriparatide
- First posted
- 2008-09-25
- Last updated
- 2017-05-11
- Results first posted
- 2017-03-28
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Lumbar Spine Bone Mineral Density | Baseline and 6 months | Percent increase or decrease in lumbar spine bone mineral density between baseline and 6 months (treatment period) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Lumbar Spine Bone Mineral Density | Baseline and 6 months | All participants were included in analysis (intention to treat). | percentage of change | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Lumbar Spine Bone Mineral Density | Teriparatide | 5.6 | Standard Error 1.3 | percentage of change | |
| Percent Change in Lumbar Spine Bone Mineral Density | Placebo | 0.2 | Standard Error 0.7 | percentage of change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Teriparatide | 12 | |
| Overall Study | STARTED | Placebo | 11 | |
| Overall Study | COMPLETED | Teriparatide | 12 | |
| Overall Study | COMPLETED | Placebo | 11 | |
| Overall Study | NOT COMPLETED | Teriparatide | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lightheadedness | Nervous system disorders | Teriparatide | 4 | 12 | |
| other | Lightheadedness | Nervous system disorders | Placebo | 6 | 12 | |
| other | Muscle pain/spasm | Musculoskeletal and connective tissue disorders | Teriparatide | 3 | 12 | |
| other | Muscle pain/spasm | Musculoskeletal and connective tissue disorders | Placebo | 4 | 12 | |
| other | Nausea | Gastrointestinal disorders | Teriparatide | 1 | 12 | |
| other | Nausea | Gastrointestinal disorders | Placebo | 5 | 12 | |
| other | Vomiting | Gastrointestinal disorders | Teriparatide | 1 | 12 | |
| other | Vomiting | Gastrointestinal disorders | Placebo | 3 | 12 | |
| other | Headache | Nervous system disorders | Teriparatide | 6 | 12 | |
| other | Headache | Nervous system disorders | Placebo | 5 | 12 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Teriparatide | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Teriparatide | 12 | 12 |
| Total, other adverse events | Placebo | 9 | 12 |
| Total, serious adverse events | Teriparatide | 2 | 12 |
| Total, serious adverse events | Placebo | 3 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Teriparatide vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00759772
GET https://conductscience.org/api/trials/v1/NCT00759772/registered